HPV mRNA test in women with minor cervical lesions: Experience of the University Hospital of North Norway

Journal of Virological Methods

Volumn 169, Issue 1, 2010, Pages 219-222

  Sorbye, S W ^a   Fismen, S ^a   Gutteberg, T J ^a,b   Mortensen, E S ^a,b  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Cervical cancer; Cytology; Dysplasia; HPV; MRNA; Screening

Indexed keywords

MESSENGER RNA; VIRUS DNA;

ADULT; AGED; ARTICLE; CANCER SCREENING; CONTROLLED STUDY; DISEASE SEVERITY; DNA DETERMINATION; EMERGENCY HEALTH SERVICE; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; NORWAY; PAPANICOLAOU TEST; PREDICTION; PRIORITY JOURNAL; RNA ANALYSIS; SENSITIVITY AND SPECIFICITY; UNIVERSITY HOSPITAL; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; UTERINE CERVIX DYSPLASIA; VIRUS DETECTION; WART VIRUS;

BIOPSY; CERVIX UTERI; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; NORWAY; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREDICTIVE VALUE OF TESTS; RNA, MESSENGER; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; VIROLOGY;

HUMAN PAPILLOMAVIRUS;

EID: 77956186903     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2010.07.011     Document Type: Article

References (20)

1. Arbyn M., Buntinx F., Van Ranst M., Paraskevaidis E., Martin-Hirsch P., Dillner J. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J. Natl. Cancer Inst. 2004, 96:280-293.
2. Arbyn M., Kyrgiou M., Simoens C., Raifu A.O., Koliopoulos G., Martin-Hirsch P., Prendiville W., Paraskevaidis E. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ 2008, 337:a1284.
3. Arbyn M., Paraskevaidis E., Martin-Hirsch P., Prendiville W., Dillner J. Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence. Gynecol. Oncol. 2005, 99:S7-11.
4. Arbyn M., Sasieni P., Meijer C.J., Clavel C., Koliopoulos G., Dillner J. Chapter 9: clinical applications of HPV testing: a summary of meta-analyses. Vaccine 2006, 24(Suppl. 3). S3-78-S3/89.
5. Basu P., Roychowdhury S., Bafna U.D., Chaudhury S., Kothari S., Sekhon R., Saranath D., Biswas S., Gronn P., Silva I., Siddiqi M., Ratnam S. Human papillomavirus genotype distribution in cervical cancer in India: results from a multi-center study. Asian Pac. J. Cancer Prev. 2009, 10:27-34.
6. Cattani P., Siddu A., D'Onghia S., Marchetti S., Santangelo R., Vellone V.G., Zannoni G.F., Fadda G. RNA (E6 and E7) assays versus DNA (E6 and E7) assays for risk evaluation for women infected with human papillomavirus. J. Clin. Microbiol. 2009, 47:2136-2141.
7. Cattani P., Zannoni G.F., Ricci C., D'Onghia S., Trivellizzi I.N., Di Franco A., Vellone V.G., Durante M., Fadda G., Scambia G., Capelli G., De Vincenzo R. Clinical performance of human papillomavirus E6 and E7 mRNA testing for high-grade lesions of the cervix. J. Clin. Microbiol. 2009, 47:3895-3901.
8. Collins S.I., Constandinou-Williams C., Wen K., Young L.S., Roberts S., Murray P.G., Woodman C.B. Disruption of the E2 gene is a common and early event in the natural history of cervical human papillomavirus infection: a longitudinal cohort study. Cancer Res. 2009, 69:3828-3832.
9. Hovland S., Muller S., Skomedal H., Mints M., Bergstrom J., Wallin K.L., Karlsen F., Johansson B., Andersson S. E6/E7 mRNA expression analysis: a test for the objective assessment of cervical adenocarcinoma in clinical prognostic procedure. Int. J. Oncol. 2010, 36:1533-1539.
10. Keegan H., Mc Inerney J., Pilkington L., Gronn P., Silva I., Karlsen F., Bolger N., Logan C., Furuberg L., O'Leary J., Martin C. Comparison of HPV detection technologies: Hybrid capture 2, PreTect HPV-Proofer and analysis of HPV DNA viral load in HPV16, HPV18 and HPV33 E6/E7 mRNA positive specimens. J. Virol. Methods 2009, 155:61-66.
11. Kraus I., Molden T., Holm R., Lie A.K., Karlsen F., Kristensen G.B., Skomedal H. Presence of E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33, and 45 in the majority of cervical carcinomas. J. Clin. Microbiol. 2006, 44:1310-1317.
12. Lie A.K., Risberg B., Borge B., Sandstad B., Delabie J., Rimala R., Onsrud M., Thoresen S. DNA- versus RNA-based methods for human papillomavirus detection in cervical neoplasia. Gynecol. Oncol. 2005, 97:908-915.
13. McCredie M.R., Sharples K.J., Paul C., Baranyai J., Medley G., Jones R.W., Skegg D.C. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 2008, 9:425-434.
14. Molden T., Nygard J.F., Kraus I., Karlsen F., Nygard M., Skare G.B., Skomedal H., Thoresen S.O., Hagmar B. Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: a 2-year follow-up of women with ASCUS or LSIL Pap smear. Int. J. Cancer 2005, 114:973-976.
15. Smith J.S., Lindsay L., Hoots B., Keys J., Franceschi S., Winer R., Clifford G.M. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int. J. Cancer 2007, 121:621-632.
16. Solomon D., Schiffman M., Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J. Natl. Cancer Inst. 2001, 93:293-299.
17. Szarewski A., Ambroisine L., Cadman L., Austin J., Ho L., Terry G., Liddle S., Dina R., McCarthy J., Buckley H., Bergeron C., Soutter P., Lyons D., Cuzick J. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol. Biomarkers Prev. 2008, 17:3033-3042.
18. Trope A., Sjoborg K., Eskild A., Cuschieri K., Eriksen T., Thoresen S., Steinbakk M., Laurak V., Jonassen C.M., Westerhagen U., Jacobsen M.B., Lie A.K. Performance of human papillomavirus DNA and mRNA testing strategies for women with and without cervical neoplasia. J. Clin. Microbiol. 2009, 47:2458-2464.
19. Vintermyr O.K., Skar R., Iversen O.E., Haugland H.K. Usefulness of HPV test on cell sample from the cervix. Tidsskr. Nor Laegeforen. 2008, 128:171-173.
20. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer 2002, 2:342-350.